About Us
A Biotechnology Company to Improve Human Wellness
Using highly-efficient, soluble,
and rapid VLNP production technology in E. coli
Development of Prophylactic or Therapeutic vaccines against various emerging and mutant viral infection
-
Date of Foundation
May 02, 2016
-
Field of Business
Virus Like Nano Particle (VLNP)-based Prophylactic or Therapeutic vaccine Development
-
Core Technology
High-yield, soluble, and rapid production technology
of VLNP vaccines in E.coli
Ability for characteristics and efficacy analysis
of vaccine candidatesIntellectual Property for VLNP vaccine
production technology
Headquarters
Address
B - 218, 11, Beobwon-ro 11-gil, Songpa-gu, Seoul, Republic of Korea
R&D Center
Address
A-1709,1809~10,1904, 302, Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea
R&D area
Development of recombinant virus
vaccine manufacturing process
InThera Inc.has built most of the equipment
needed for vaccine research in the R&D center.
-
R&D Center
-
analysis room
-
Purification room
-
cell culture room
InThera INC CEO : Deog-Young Choi B-218, 11, Beobwon-ro 11-gil, Songpa-gu, Seoul, Republic of Korea TEL 82-02-6239-2570
Copyright(c) InThera, All rights reserved.